News | New analysis on the cost-effectiveness of covid-19 inactiyated vaccines in reducing the economic burden of ischaemic stroke after SARS-COV-2 infection
New analysis on the cost-effectiveness of COVID-19 inactivated vaccines in reducing the economic burden of ischaemic stroke after SARS-CoV-2 infection
May 25, 2023
A new publication in Vaccines suggests the importance of COVID-19 vaccination is not only in preventing the spread of infectious diseases, but also in considering its long-term value in reducing the economic burden of non-communicable diseases such as ischaemic stroke after SARS-CoV-2 infection.
The study aimed to explore the cost-effectiveness of the two-dose inactivated COVID-19 vaccination program in reducing the economic burden of ischaemic stroke after SARS-CoV-2 infection. Researchers constructed a decision-analytic Markov model to compare the two-dose inactivated COVID-19 vaccination strategy to the no vaccination strategy using cohort simulation, and calculated incremental cost-effectiveness ratios (ICERs) to evaluate the cost-effectiveness and used number of the ischaemic stroke cases after SARS-CoV-2 infection and quality-adjusted life-years (QALYs) to assess effects.
The findings showed that the two-dose inactivated vaccination strategy reduced ischaemic stroke cases after SARS-CoV-2 infection by 80.89% (127/157) with a USD 1.09 million as vaccination program cost, saved USD 3675.69 million as direct health care costs and gained 26.56 million QALYs compared with no vaccination strategy among 100,000 COVID-19 patients (ICER < 0 per QALY gained).
Full article link: https://www.mdpi.com/2076-393X/11/5/957
News Source: IMMUNIZATION ECONOMICS.ORG